Your browser doesn't support javascript.
loading
MiR-491-5p, as a Tumor Suppressor, Prevents Migration and Invasion of Breast Cancer by Targeting ZNF-703 to Regulate AKT/mTOR Pathway.
Guo, Jingyun; Luo, Can; Yang, Yuqin; Dong, Jianyu; Guo, Zhaoze; Yang, Jinlamao; Lian, Huining; Ye, Changsheng; Liu, Minfeng.
Afiliación
  • Guo J; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Luo C; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Yang Y; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Dong J; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Guo Z; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Yang J; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Lian H; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Ye C; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
  • Liu M; Breast Center, Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, People's Republic of China.
Cancer Manag Res ; 13: 403-413, 2021.
Article en En | MEDLINE | ID: mdl-33488122
BACKGROUND: Large amounts of microRNAs (miRNAs) have been reported to be aberrantly expressed in malignant cancers. MiR-491-5p makes a significant contribution to the inhibition of multiple cancer processes. However, the specific mechanism and function of miR-491-5p and in breast cancer (BC) is still not fully elucidated. METHODS: MiR-491-5p and ZNF-703 expressions or gene transfection effects were identified by RT-qPCR or Western blot in BC tissues or cells. And ZNF-703 expression was monitored through immunohistochemistry method. Cellular function was also confirmed using Transwell assay. Besides, AKT/mTOR pathway-related proteins were analyzed using Western blotting analysis. Moreover, the interplay between miR-491-5p and ZNF-703 was verified through dual-luciferase reporter assay. RESULTS: miR-491-5p was lowly expressed, ZNF-703 was highly expressed in BC, and miR-491-5p with low expression and ZNF-703 with high expression were associated with poor prognosis of BC patients. Results of cellular function revealed that overexpression of miR-491-5p markedly suppressed BC cell migration and invasion, and knockdown of miR-491-5p had the opposite effect. Besides, mechanism research disclosed that miR-491-5p directly could bind to ZNF-703 and downregulate ZNF-703. Moreover, we proved that ZNF-703 could prominently reverse the influences of miR-491-5p on the migration and invasion of BC cells. More importantly, the data revealed that miR-491-5p repressed AKT/mTOR pathway by ZNF-703 in BC cells. CONCLUSION: MiR-491-5p prominently suppresses the metastasis of BC cells through ZNF-703 to regulate AKT/mTOR pathway, indicating that miR-491-5p and ZNF-703 might be served as the potential therapeutic targets for BC.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancer Manag Res Año: 2021 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cancer Manag Res Año: 2021 Tipo del documento: Article